This afternoon, Turing Pharmaceuticals announced that it is lowering the price of Daraprim by up to 50 percent for hospitals. This brings the price of the drug to $375 per pill, which is still a 2,500 percent hike over the original $13.50 price. In response to the Turing announcement, John Rother, executive director of the Campaign for Sustainable Rx Pricing issued the following statement:

“While the adjusted price of Daraprim is an improvement from its original price tag, it is clear that this critical treatment is still priced far out of reach for many Americans. This same medication can be purchased overseas for $.66 a pill — a fraction of what it costs in the U.S. — which makes us question how the pharmaceutical industry can justify their outrageous and harmful pricing strategies. Today’s announcement from Turing proves that many pharmaceutical companies are more concerned with their bottom line than providing Americans with access to essential medications at an affordable price.”